

continuation or recurrence of material injury to an industry in the United States within a reasonably foreseeable time.

### Background

The Commission instituted these reviews on November 3, 2025 (90 FR 55167, December 1, 2025) and determined on March 6, 2026 that it would conduct expedited reviews (91 FR 18004, April 9, 2026).

The Commission made these determinations pursuant to section 751(c) of the Act (19 U.S.C. 1675(c)). It completed and filed its determinations in these reviews on May 15, 2026. The views of the Commission are contained in USITC Publication 5739 (May 2026), entitled *Oil Country Tubular Goods from China: Investigation Nos. 701-TA-463 and 731-TA-1159 (Third Review)*.

By order of the Commission.

Issued: May 15, 2026.

**Sharon Bellamy,**

*Supervisory Hearings and Information Officer.*

[FR Doc. 2026-10002 Filed 5-18-26; 8:45 am]

**BILLING CODE 7020-02-P**

## INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-1447]

### Certain Drug Products Containing C-Type Natriuretic Peptide Variants, and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Amending the Complaint and Notice of Investigation

**AGENCY:** U.S. International Trade Commission.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the U.S. International Trade Commission (“Commission”) has determined not to review an initial determination (“ID”) (Order No. 45) of the presiding Chief administrative law judge (“Chief ALJ”) granting complainant’s unopposed motion to amend the complaint and notice of investigation to reflect respondent Ascendis Pharma, Inc.’s corporate name change to Ascendis Pharma, LLC.

**FOR FURTHER INFORMATION CONTACT:** Jonathan D. Link, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205-3103. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket (EDIS)

at <https://edis.usitc.gov>. For help accessing EDIS, please email [EDIS3Help@usitc.gov](mailto:EDIS3Help@usitc.gov). General information concerning the Commission may also be obtained by accessing its internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205-1810.

**SUPPLEMENTARY INFORMATION:** The Commission instituted this investigation on May 8, 2025, based on a complaint filed by BioMarin Pharmaceutical Inc. of Novato, CA (“Complainant”). 90 FR 19532-33 (May 8, 2025). The complaint, as supplemented, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain drug products containing C-type natriuretic peptide variants and components thereof by reason of infringement of claims 15-20, and 31-48 of RE’267 patent. *Id.* The complaint further alleges that a domestic industry exists. *Id.* The Commission’s notice of investigation named as respondents: Ascendis Pharma, Inc. of Palo Alto, California; Ascendis Pharma A/S of Hellerup, Denmark; Ascendis Pharma Growth Disorders A/S of Hellerup, Denmark (collectively “Ascendis”); and Wacker Biotech GmbH of Jena, Germany. *Id.* The Office of Unfair Import Investigations (“OUII”) is participating in the investigation. *Id.*

On September 12, 2025, the Commission determined not to review Order No. 15 granting Complainant’s motion to amend the complainant and notice of investigation to add Bachem Ag as an additional respondent. *See* Order No. 15 (Aug. 14, 2025), *unreviewed by Comm’n Notice* (Sept. 12, 2025), 90 FR 44843 (Sept. 17, 2025).

On March 23, 2026, the Commission determined not to review an initial determination (Order No. 36) terminating from the investigation claims 15-22, 31, 33, 35-40, 42, 44, and 45-48 of the RE’267 patent, with claims 21-22 having been asserted for domestic industry purposes only. *See* Order No. 36 (Mar. 3, 2026), *unreviewed by Comm’n Notice* (Mar. 23, 2026).

On April 14, 2026, Complainant filed a motion to amend the amended complaint and notice of investigation to reflect respondent Ascendis Pharma, Inc.’s corporate name change to Ascendis Pharma, LLC. No responses to the motion were filed.

On April 27, 2026, the ALJ issued the subject ID (Order No. 45), granting

Complainant’s unopposed motion to amend the amended complaint and notice of investigation. No petitions for review of the ID were filed.

The Commission has determined not to review the subject ID. The notice of investigation is amended to reflect respondent Ascendis Pharma, Inc.’s corporate name change to Ascendis Pharma, LLC.

The Commission vote for this determination took place on May 15, 2026.

The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: May 15, 2026.

**Sharon Bellamy,**

*Supervisory Hearings and Information Officer.*

[FR Doc. 2026-10010 Filed 5-18-26; 8:45 am]

**BILLING CODE 7020-02-P**

## NUCLEAR REGULATORY COMMISSION

[Docket No. M70-7033-ML; ASLBP No. 26-992-01-ML-BD02]

### Global Laser Enrichment, LLC; Establishment of Atomic Safety and Licensing Board

Pursuant to the Commission’s regulations, *see, e.g.*, 10 CFR 2.104, 2.105, 2.300, 2.309, 2.313, 2.318, 2.321, notice is hereby given that an Atomic Safety and Licensing Board (Board) is being established to preside over the following proceeding:

GLOBAL LASER ENRICHMENT, LLC (Paducah Laser Enrichment Facility)  
Global Laser Enrichment, LLC (GLE) has applied for a license to possess and use special nuclear material for the purpose of constructing and operating a uranium enrichment facility in McCracken County, Kentucky. The requested license would authorize the facility to re-enrich depleted uranium hexafluoride tails and enrich natural-grade uranium hexafluoride to a maximum of 8-weight percent uranium-235 via laser-based isotope separation technology.

Because GLE is seeking authorization to construct a uranium enrichment facility, pursuant to Section 193 of the Atomic Energy Act, as amended (42 U.S.C. 2243), and 10 CFR 70.23a, an uncontested mandatory hearing will be conducted following completion of the NRC staff’s safety evaluation and

environmental review of GLE's license application. See 91 FR 11,092, 11,093 (Mar. 6, 2026). A Board will conduct that hearing. See *id.*

The Board is comprised of the following Administrative Judges:

Emily I. Krause, Chair, Atomic Safety and Licensing Board Panel, U.S.

Nuclear Regulatory Commission,

Washington, DC 20555-0001

Dr. David A. Smith, Atomic Safety and Licensing Board Panel, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001

Dr. Arielle J. Miller, Atomic Safety and Licensing Board Panel, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001

All correspondence, documents, and other materials shall be filed in accordance with the NRC E-Filing rule. See 10 CFR 2.302.

Rockville, Maryland.

Dated: May 14, 2026.

**Edward R. Hawkens,**

Chief Administrative Judge, Atomic Safety and Licensing Board Panel.

[FR Doc. 2026-09949 Filed 5-18-26; 8:45 am]

**BILLING CODE 7590-01-P**

## POSTAL REGULATORY COMMISSION

[Docket Nos. MC2026-244 and K2026-242; MC2026-245 and K2026-243; MC2026-246 and K2026-244; MC2026-247 and K2026-245]

### New Postal Products

**AGENCY:** Postal Regulatory Commission.

**ACTION:** Notice.

**SUMMARY:** The Commission is noticing a recent Postal Service filing for the Commission's consideration concerning a negotiated service agreement. This notice informs the public of the filing, invites public comment, and takes other administrative steps.

**DATES:** *Comments are due:* May 22, 2026.

**ADDRESSES:** Submit comments electronically via the Commission's Filing Online system at <https://www.prc.gov>. Those who cannot submit comments electronically should contact the person identified in the **FOR FURTHER INFORMATION CONTACT** section by telephone for advice on filing alternatives.

**FOR FURTHER INFORMATION CONTACT:** David A. Trissell, General Counsel, at 202-789-6820.

### SUPPLEMENTARY INFORMATION:

#### Table of Contents

##### I. Introduction

##### II. Public Proceeding(s)

##### III. Summary Proceeding(s)

### I. Introduction

Pursuant to 39 CFR 3041.405, the Commission gives notice that the Postal Service filed request(s) for the Commission to consider matters related to Competitive negotiated service agreement(s). The request(s) may propose the addition of a negotiated service agreement from the Competitive product list or the modification of an existing product currently appearing on the Competitive product list.

The public portions of the Postal Service's request(s) can be accessed via the Commission's website (<http://www.prc.gov>). Non-public portions of the Postal Service's request(s), if any, can be accessed through compliance with the requirements of 39 CFR 3011.301.<sup>1</sup>

Section II identifies the docket number(s) associated with each Postal Service request, if any, that will be reviewed in a public proceeding as defined by 39 CFR 3010.101(p), the title of each such request, the request's acceptance date, and the authority cited by the Postal Service for each request. For each such request, the Commission appoints an officer of the Commission to represent the interests of the general public in the proceeding, pursuant to 39 U.S.C. 505 and 39 CFR 3000.114 (Public Representative). The Public Representative does not represent any individual person, entity or particular point of view, and, when Commission attorneys are appointed, no attorney-client relationship is established. Section II also establishes comment deadline(s) pertaining to each such request.

The Commission invites comments on whether the Postal Service's request(s) identified in Section II, if any, are consistent with the policies of title 39. Applicable statutory and regulatory requirements include 39 U.S.C. 3632, 39 U.S.C. 3633, 39 U.S.C. 3642, 39 CFR part 3035, and 39 CFR part 3041. Comment deadline(s) for each such request, if any, appear in Section II.

Section III identifies the docket number(s) associated with each Postal Service request, if any, to add a standardized distinct product to the Competitive product list or to amend a standardized distinct product, the title of each such request, the request's acceptance date, and the authority cited by the Postal Service for each request. Standardized distinct products are

negotiated service agreements that are variations of one or more Competitive products, and for which financial models, minimum rates, and classification criteria have undergone advance Commission review. See 39 CFR 3041.110(n); 39 CFR 3041.205(a). Such requests are reviewed in summary proceedings pursuant to 39 CFR 3041.325(c)(2) and 39 CFR 3041.505(f)(1). Pursuant to 39 CFR 3041.405(c)-(d), the Commission does not appoint a Public Representative or request public comment in proceedings to review such requests. The comment due date discussed below does not apply to Section III proceedings (Docket Nos. MC2026-245 and K2026-243; MC2026-246 and K2026-244; MC2026-247 and K2026-245).

### II. Public Proceeding(s)

1. *Docket No(s):* MC2026-244 and K2026-242; *Filing Title:* USPS Request to Add Priority Mail Express International, Priority Mail International & First-Class Package International Service Contract 114 to Competitive Product List and Notice of Filing Materials Under Seal; *Filing Acceptance Date:* May 14, 2026; *Filing Authority:* 39 U.S.C. 3642, 39 CFR 3035.105, and 39 CFR 3041.310; *Public Representative:* Kenneth Moeller; *Comments Due:* May 22, 2026.

### III. Summary Proceeding(s)

1. *Docket No(s):* MC2026-245 and K2026-243; *Filing Title:* USPS Request to Add New Fulfillment Standardized Distinct Product, PM-GA Contract 989, and Notice of Filing Materials Under Seal; *Filing Acceptance Date:* May 14, 2026; *Filing Authority:* 39 U.S.C. 3642 and 3633, 39 CFR 3035.105, and 39 CFR 3041.325.

2. *Docket No(s):* MC2026-246 and K2026-244; *Filing Title:* USPS Request to Add New Fulfillment Standardized Distinct Product, PM-GA Contract 990, and Notice of Filing Materials Under Seal; *Filing Acceptance Date:* May 14, 2026; *Filing Authority:* 39 U.S.C. 3642 and 3633, 39 CFR 3035.105, and 39 CFR 3041.325.

3. *Docket No(s):* MC2026-247 and K2026-245; *Filing Title:* USPS Request to Add New Fulfillment Standardized Distinct Product, PM-GA Contract 991, and Notice of Filing Materials Under Seal; *Filing Acceptance Date:* May 14, 2026; *Filing Authority:* 39 U.S.C. 3642 and 3633, 39 CFR 3035.105, and 39 CFR 3041.325.

<sup>1</sup> See Docket No. RM2018-3, Order Adopting Final Rules Relating to Non-Public Information, June 27, 2018, Attachment A at 19-22 (Order No. 4679).